Company Overview and News

2
Radient Technologies Inc. receives Controlled Drugs and Substances Licence for its Manufacturing Facility

2018-10-09 globenewswire
EDMONTON, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) is pleased to announce that it has received its Controlled Drugs and Substances Licence, also known as a Dealer’s Licence (the “Licence”), from Health Canada’s Office of Controlled Substances for its Manufacturing Facility located at 4035 – 101 NW Street, Edmonton, Alberta.
ACB ACBFF RTI

13
Getting 'High' With A Cannabis-Related Investment In Psychemedics

2018-09-21 seekingalpha
When members of my anti-pharma, anti-tobacco, anti-alcohol stock club suggested investing in cannabis several months ago, I was surprised. So, I promptly found a good reason to stall.
STZ.B WEED RTI PMD RDDTF STZ CGC SMG

11
The Best 'Pick And Shovel' Plays Of Cannabis (Part II)

2018-09-21 seekingalpha - 1
In this article, we will discuss three more companies that all focus on the technologies that can be used in the cannabis industry.
LXX EVIO RTI BSTI RDDTF TLRY LXRP SMG

 
Radient Technologies Inc. Unaware of Any Material Change

2018-09-18 globenewswire
EDMONTON, Alberta, Sept. 18, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC, Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
RTI

3
Radient Technologies Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

2018-08-28 globenewswire - 1
EDMONTON, Alberta, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) is pleased to announce financial results for the first fiscal quarter ended June 30, 2018 and provide a corporate update. The Financial statements are available on www.SEDAR.com.
ACB ACBFF RTI

92
The BAK Portfolio: Canadian Weed Is Legal And The Green Rush Has Begun

2018-07-17 seekingalpha
An escalating trade war and a tepid rebound in Canadian cannabis stocks left the portfolio running in the red for the second quarter in a row.
LXX TAP GRWG TWMJF KHRNF MICWF WEED RTI APHQF CGC LXRP

3
Cannabis Act Regulations Indicative of Radient Technologies’ Role in Industrial-Scale Cannabis and Hemp Value Chains

2018-07-06 globenewswire - 1
EDMONTON, Alberta, July 06, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI), is encouraged by Health Canada’s recently introduced Cannabis Regulations and Industrial Hemp Regulations in accordance with the Cannabis Act – a new legal framework that puts in place a comprehensive public health approach to cannabis in Canada.
ACB ACBFF RTI

30
Canadian Legalization: What's Next For Cannabis Stocks?

2018-06-21 seekingalpha
On June 19, 2018, the Canadian Senate passed The Cannabis Act 52 to 29. The rest of the approval process will be completed before the end of the week.
SNNVF KHRNF ACBFF RTI DTK CGC GSK LXX TWMJF ACB WEED RDDTF OGRMF OGI LXRP

 
Radient Technologies Inc. Files FDA Submission for Reducing Nicotine in Tobacco

2018-06-12 globenewswire
EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has made a submission to the U.S. Food and Drug Administration (the “FDA”) to consider the Company’s proprietary technology as a method to reduce nicotine levels in tobacco.
RTI

9
Aurora Cannabis Makes Strategic Investment in CTT Pharmaceutical

2018-05-22 globenewswire
Edmonton, AB, May 22, 2018 (GLOBE NEWSWIRE) -- Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CTT Pharmaceutical Holdings Inc. ("CTT") (US-OTC: CTTH) today announced that Aurora is acquiring an initial 9.14% ownership interest in CTT via way of a non-brokered private placement in the form of a US$1 million 5% convertible debenture. The agreement includes an issuance of warrants enabling Aurora to increase ownership to 42.
ACB CTTH ACBFF RTI TXCX CNGGF

 
Weekly Cannabis Report: Aurora/MedReleaf, Canopy, Maricann

2018-05-15 seekingalpha
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis.
CRON RTI RDDTF CCAN MEDFF HMPPF

17
Aurora: Q3 2018, Another Solid Quarter Eclipsed By M&A Rumor

2018-05-10 seekingalpha
Revenue grew 38% driven by other revenue outside cannabis sales, which only increased 11% during the quarter.
TWMJF ACBFF WEED RTI LQSIF APHQF RDDTF CNGGF MEDFF HMPPF

 
Radient Technologies: A Cannabis And Hemp Extraction Expert

2018-05-06 seekingalpha
Since Radient acquired the MAP technology from Canadian Government the firm has struggled to commercialize the extraction process.
RTI HRVOF HMPPF

8
Radient Technologies - Excellent Growth Expected Over The Next Few Years

2018-05-05 seekingalpha
Radient continues to see steady revenue growth. The company also has excellent cash on hand to continue to grow its operations.
ACB ACBFF RTI RDDTF

8
Radient Technologies Inc. Announces Closing of Real Estate Transactions

2018-05-03 globenewswire
EDMONTON, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce it has completed its previously announced real estate acquisitions (please see the Company’s April 18, 2018 news release).
ACB ACBFF RTI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:RTI / Radient Technologies Inc on message board site Silicon Investor.

Point and Figure Charting Point and Figure Charting Point and Figure Charting Robotics and Artificial Intelligence Robotics and Artificial Intelligence Robotics and Artificial Intelligence
The abortion issue: pro-choice vs. anti-abortion The abortion issue: pro-choice vs. anti-abortion The abortion issue: pro-choice vs. anti-abortion Microcap Potential Homeruns--Credible, and Reporting Microcap Potential Homeruns--Credible, and Reporting Microcap Potential Homeruns--Credible, and Reporting
Novartis Novartis Novartis Lockheed Martin (LMT) Lockheed Martin (LMT) Lockheed Martin (LMT)
Naked Shorting-Hedge Fund u0026 Market Maker manipulation? Naked Shorting-Hedge Fund u0026 Market Maker manipulation? Naked Shorting-Hedge Fund u0026 Market Maker manipulation? GOPwinger Lies/Distortions/Omissions/Perversions of Truth GOPwinger Lies/Distortions/Omissions/Perversions of Truth GOPwinger Lies/Distortions/Omissions/Perversions of Truth
Donald Trump is a fraud and a Con Artist - not a conservativ Donald Trump is a fraud and a Con Artist - not a conservativ Donald Trump is a fraud and a Con Artist - not a conservativ Fertilizer African Plays (PCP.V, FED.V) Fertilizer African Plays (PCP.V, FED.V) Fertilizer African Plays (PCP.V, FED.V)